Role of angiotensin II in injury-induced neointima formation in rats.

Angiotensin converting enzyme inhibition markedly suppresses neointima formation in response to balloon catheter-induced vascular injury of the rat carotid artery. To determine whether this effect was mediated through the vasoactive peptide angiotensin II (Ang II), two approaches were followed. First, the balloon model was used to compare the effects of continuous infusion of Ang II, with and without concurrent converting enzyme inhibition by cilazapril; second, the effects of the orally active nonpeptidic Ang II receptor antagonist DuP 753 were analyzed. Morphometric analysis was performed at 14 days after balloon injury. Animals that received continuous infusion of Ang II (0.3 micrograms/min/rat) were found to have significantly greater neointima formation in response to balloon injury than controls. Animals treated with cilazapril (10 mg/kg/day) had markedly reduced neointima formation, but in animals receiving infusion of Ang II, treatment with cilazapril did not suppress development of neointimal lesions. In the second group of experiments, DuP 753 (10 mg/kg twice daily) was as effective to prevent neointima formation as cilazapril. These data support the conclusions that converting enzyme inhibition prevents neointima formation after vascular injury through inhibition of Ang II generation.

Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy.

Ro 40-5967 is a structurally novel Ca2+ channel blocker which binds to the [3H]desmethoxyverapamil receptor in cardiac membranes with a potency similar to that of verapamil but which has considerably fewer negative inotropic effects. In the present study, the inward Ca2+ current was measured in isolated myocytes with the whole-cell patch-clamp technique. It was found that at a physiological membrane potential (-80 mV) Ro 40-5967 was also less potent than verapamil in inhibiting this current, and that negative inotropy and Ca2+ channel blockade were correlated.

The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.

Ro 40-5967 is a structurally novel Ca2+ channel blocker that binds to the verapamil-type receptor of cardiac membranes but that has been shown in isolated guinea-pig hearts to be about ten times less potent a negative inotropic agent than verapamil. The goals of the present study were to confirm these findings in vitro in isolated perfused rat hearts as well as in vivo in conscious rats and to compare Ro 40-5967 to verapamil. The effects of Ro 40-5967 and verapamil were tested not only in normal rats, but also in rats with heart failure induced by chronic myocardial infarction. In isolated Langendorff hearts (without heart failure), no decrease of contractility was observed with Ro 40-5967 up to complete AV block. In contrast, verapamil decreased contractility with an IC50 of 100 nM. In isolated, electrically stimulated rat papillary muscles, the IC50 values for the decrease of contractile force were 15,000 and 440 nM for Ro 40-5967 and verapamil, respectively. In vivo, Ro 40-5967 did not decrease left ventricular contractility (as assessed by changes of dP/dt max +) in rats without and with heart failure. In contrast, verapamil was markedly negative inotropic in both conditions.

Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil.

(1S,2S)-2-[2-[[3-(2-Benzimidazolyl)propyl]methylamino]ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride (Ro 40-5967) is a novel calcium antagonist. Its effect on systolic arterial blood pressure and heart rate was investigated in comparison with verapamil in conscious spontaneously hypertensive rats (SHR), renal hypertensive rats (2K1C), deoxycorticosterone acetate (DOCA)-NaCl hypertensive rats and normotensive Wistar rats. After single oral doses, Ro 40-5967 (3-30 mg/kg) and verapamil (10-100 mg/kg) produced a dose-related decrease in blood pressure in all three types of hypertensive rats. Ro 40-5967 was 3-5 times more potent than verapamil. DOCA-NaCl hypertensive rats were more sensitive to the antihypertensive action of Ro 40-5967 than renal hypertensive rats and SHR. Both compounds lowered blood pressure of normotensive rats to a lesser degree than that of hypertensive rats. The antihypertensive effects of Ro 40-5967 and verapamil occurred fast, with similar efficacies and reached maximal values 3 and 6 h postdrug (SHR). While the significant antihypertensive effect of Ro 40-5967 (30 mg/kg) persisted for 24 h, that of verapamil (100 mg/kg) recovered completely 16 h postdrug. The experimental data suggest that Ro 40-5967 might be suitable for clinical use as a once-a-day antihypertensive agent.

Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil.

Ro 40-5967 is a structurally novel calcium antagonist that binds to the verapamil binding site but has very weak negative inotropic effects compared to verapamil. The goals of the present study were to assess the effects of Ro 40-5967 on myocardial function during ischemia, and to compare them to those of verapamil. For this purpose, in anesthetized dogs where the circumflex coronary artery was cannulated and perfused at controlled pressure, myocardial function was measured using piezo electric crystals implanted into the endocardium. Myocardial distribution of coronary blood flow was assessed using radioactive microspheres. Ischemia was produced by lowering perfusion pressure from 100 to 15 mm Hg in steps. During ischemia, Ro 40-5967 partially prevented the decrease of segmental shortening (p less than 0.01) and increased coronary flow, especially in the endocardium (p less than 0.01). In contrast, verapamil did not improve myocardial function during ischemia. The protective effect of Ro 40-5967 could be partially explained by the decrease of arterial pressure and heart rate induced by Ro 40-5967. However, Ro 40-5967 injected directly inside the coronary artery did not induce systemic effects, but still had protective effects (p less than 0.05). Verapamil injected intracoronary produced severe cardiac depression. We conclude that in the present model during ischemia Ro 40-5967 has no negative inotropic effects, and in contrast to verapamil can improve the myocardial function.

In vitro pharmacological properties of a series of isoprenaline derivatives.

The p-trifluoromethylanilide congener of isoprenaline, tert-butyl N-[(S)[( 4-[(R)-6-[2-(3,4-dihydroxyphenyl-2- hydroxyethyl]amino]heptanamido]phenyl]methyl][(N-methylcarbamoy l) methyl]carbamoyl]methyl]carbamate (1S,4R)-4,7,7-trimethyl-3-oxo-2- oxabicyclo[2.2.1]heptane-1-carboxylate (1:1) (Ro 17-2218) was investigated for its effects in various pharmacological tests in vitro and compared to the parent compound. As Ro 17-2218 represented a mixture of four diastereomers, the pure isomers were synthesized. They had a purity of 97-98%. By pharmacological testing of the diastereomers the highest potency was found in the 6R,2'R-isomer Ro 17-8648, while the potency of the 6S,2'S-isomer, Ro 17-9651 was lower by three orders of magnitude. The amorphous hydrochloride Ro 17-8648/001 had 1/10 the potency of the respective crystalline camphanate Ro 17-8648/003. (R)-6-[(R)-[2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]-N-[4- (trifluoromethyl) phenyl]heptan amide (Ro 17-8648/003) was found to have potent beta-agonist properties with clear beta 1-selectivity in radioligand binding studies. It exerted an extremely tight binding to membrane receptors. As a full beta-agonist it elicited positive inotropic effects in isolated cardiac tissues, with a potency 10-360 times that of isoprenaline and an extremely long duration of action. Electrophysiological studies in isolated guinea-pig papillary muscles confirmed the beta 1-receptor-mediated effects of the compound.

In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action.

Ro 40-5967 is a structurally novel Ca2+ channel blocker which binds to the verapamil-type receptor of cardiac membranes. Its biological activity was investigated in comparison with verapamil in isolated vascular, cardiac, and gastrointestinal muscle preparations, as well as in isolated perfused hearts. Ro 40-5967 was more potent in increasing coronary artery flow (EC50 = 54 nM) than in suppressing myocardial (IC50 = 14,000 nM) and peripheral vascular (aortic) contractility half-maximal inhibition (IC50 = 275 nM). In contrast, verapamil was equally potent in affecting all three variables. These observations demonstrate an apparent preference of Ro 40-5967 for the coronary vasculature, as opposed to verapamil, in vitro. Results also suggest that Ro 40-5967 is less potent than verapamil in gastrointestinal smooth muscle.

Ro 15-4513: partial inverse agonism at the BZR and interaction with ethanol.

The imidazobenzodiazepinone derivative Ro 15-4513 has the activity profile of a partial inverse (low efficacy) agonist at the benzodiazepine receptor (BZR). It reverses central nervous depressant effects of diazepam, and, in part, of phenobarbitone and ethanol in mice, rats and cats in behavioural, electrophysiological, and neurochemical paradigms. The interaction of Ro 15-4513 with barbiturates and ethanol is due to its inverse agonistic (negative allosteric modulatory) property at the BZR, as it was reversed by the selective BZR blocker flumazenil (Ro 15-1788). In the present experiment situations, other BZR partial inverse agonists in subconvulsant or overt convulsant doses were less effective against ethanol effects than Ro 15-4513. Possible mechanisms for this differential activity of BZR inverse agonists are discussed.

Interaction of the cardiotonic agent DPI 201-106 with cardiac Ca2+ channels.

The cardiotonic agent DPI 201-106 was investigated for its effects on (a) contractile force in guinea pig left atria, (b) membrane currents in isolated guinea pig cardiac myocytes, and (c) [3H]nitrendipine binding in guinea pig cardiac membranes. The compound elicited a positive inotropic effect in normally polarized (5.9 mM extracellular KCl) and a negative inotropic effect in partially depolarized (20 mM KCl) isolated, electrically stimulated left atria. This decrease in contractile force was probably caused by inactivation of the fast Na+ inward current and concomitant blockade of the inward Ca2+ current. The blocking effect on Ca2+ channels was directly shown in voltage-clamp experiments using isolated cardiocytes. Further evidence for interaction of DPI 201-106 with Ca2+ channels was obtained from the [3H]nitrendipine binding studies. Thus, Ca2+ antagonism contributes to the complex pharmacologic profile of DPI 201-106, and is probably responsible for the bradycardia and lowering of systemic vascular resistance observed in vivo.

Modification of K+ conductance of heart cell membrane by BRL 34915.

1. The effect of the K+ channel agonist BRL 34915 on membrane conductance was investigated in isolated guinea-pig cardiac myocytes. 2. BRL 34915 reduced the duration of the transmembrane action potential and slightly increased the membrane resting potential in a concentration-dependent manner. 3. BRL 34915 removed the rectification in the steady-state current-voltage relationship. At membrane potentials more negative than the K+ equilibrium potential, membrane conductance was reduced. In the presence of 10(-4) mol/l BRL 34915, the current-voltage relationship was linear, i.e. of an ohmic type. 4. The BRL 34915-mediated change in membrane conductance was susceptible to the K+ channel blockers BaCl2 and tetrahydroaminoacridine. 5. In conclusion, BRL 34915 modifies K+ conductance in the cardiac cell membrane. The precise nature of the K+ conductance change remains to be elucidated.

9-Amino-1,2,3,4-tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels.

1. 9-Amino-1,2,3,4-tetrahydroacridine (THA) is a compound with structural similarity to the K+ channel blocker 4-aminopyridine. It was investigated for its effects on myocardial membrane currents in guinea-pig isolated ventricular myocytes. 2. THA prolonged the transmembrane action potential and decreased the amplitude of its plateau in a reversible manner. 3. Voltage-clamp experiments showed that THA reduced the inwardly rectifying and the time-dependent outward K+ currents as well as the slow inward Ca2+ current. 4. The degree of block of the inwardly rectifying K+ current depended on the membrane potential, being more pronounced at more positive potentials.

Effects of chronic myocardial infarction on responsiveness to isoprenaline and the state of myocardial beta adrenoceptors in rats.

Responsiveness to catecholamines and alterations in myocardial beta adrenoceptors were determined in rats with chronic myocardial infarction. Myocardial infarction was produced by ligating the left main coronary artery. Three weeks after myocardial infarction, when left ventricular function was impaired, catecholamine responsiveness was determined by measuring the effects of isoprenaline in the conscious animal, the isolated perfused heart, the isolated right atria, and the right papillary muscles. The catecholamine content and the density and affinity of beta adrenergic receptors [( 3H]dihydroalprenolol binding) were determined in non-ischaemic myocardium (ventricular septum). In conscious rats isoprenaline induced the same tachycardia in the sham operated as in the rats with infarction, but it induced only a slight increase of myocardial contractility because of a high basal sympathetic tone. In isolated perfused hearts, right atria, and right papillary muscles isoprenaline increased contractile force and heart rate with the same EC50 in both groups. However, in the infarcted group the maximal increase of contractile force induced by isoprenaline was smaller because of mechanical limitation due to the infarction. The catecholamine content was decreased in non-ischaemic myocardium and beta adrenergic density was increased by 30% (p less than 0.02) without any change of affinity. Thus in rats chronic myocardial infarction does not change the responsiveness of the non-ischaemic myocardium to isoprenaline and is not associated with a downregulation of the beta adrenoceptors.

Inhibition of myocardial Ca2+ channels by three dihydropyridines with different structural features: potential-dependent blockade by Ro 18-3981.

Inhibition of myocardial Ca2+ channels was investigated for three dihydropyridines with different structural features: Ro 18-3981, darodipine (PY 108-068) and nifedipine. Ro 18-3981 contains a sulphamoyl acetyl side-chain. In voltage-clamps experiments with isolated cardiac myocytes of guinea-pig, Ro 18-3981 caused a concentration-dependent inhibition of the Ca2+ current, which was influenced by the membrane holding potential. A markedly greater inhibition by Ro 18-3981 was observed when myocytes were depolarized (to +10 mV) from a holding potential (Vh) of -20 mV (IC50 = 2.3 nm) than at -50 mV (IC50 = 100 nM). The three dihydropyridines caused a concentration-dependent reduction in contractile force of isolated, electrically-stimulated left atria of the guinea-pig. Elevation of the extracellular K+ concentration from 5.9 to 24 mM resulted in a significant reduction in negative inotropic IC50 values for Ro 18-3981 (137 fold), darodipine (8 fold) and nifedipine (20 fold). The affinity of these drugs for the high-affinity (+)-[3H]-PN 200-110 binding site was determined in guinea-pig cardiac membranes. The KD value of Ro 18-3981 (1.0 nM) was similar to the IC50 value for blockade of ICa at a Vh of -20 mV (2.3 nM), i.e. at a level of near-maximal depolarization. Thus, structurally-different dihydropyridines exert potential-dependent inhibition of myocardial Ca2+ channel activity consistent with the modulated receptor hypothesis. These results demonstrate that blockade of myocardial excitation-contraction coupling by Ca2+ entry blockers is also potential-dependent.

Inhibition of the fast Na+ inward current by the Ca2+ channel blocker tiapamil.

The inhibitory effect of the phenylalkylamine-type Ca2+-entry blocker, tiapamil, on the fast Na+ inward current was investigated in guinea-pig papillary muscles by measuring the maximum upstroke velocity (dV/dt)max of transmembrane action potentials. Tiapamil inhibited (dV/dt)max at concentrations above 10(-6) M, with an IC50 value of 7 X 10(-5) M (1 Hz stimulation frequency, 5.9 mM extracellular K+). Verapamil was less potent in depressing upstroke velocity. Inhibition of the dV/dtmax strongly depended on the frequency at which the muscles were stimulated ("use-dependent" effect). There was no evidence that tiapamil acts in a potential-dependent manner like local anesthetics. The results indicate that the Ca2+-entry blocker tiapamil has additional pharmacological properties, which may contribute to its usefulness in the treatment of ventricular arrhythmias.

o-Isothiocyanate dihydropyridine (oNCS-DHP), a long-acting, reversible inhibitor of the Ca++ channel.

The binding characteristics and pharmacological properties of o-isothiocyanate dihydropyridine [oNCS-DHP; 2,6-dimethyl-3,5-dicarbomethoxy-4-(2-isothiocyanatophenyl)-1, 4-dihydropyridine] were investigated in guinea pig heart and ileum. [3H]oNCS-DHP bound to a single population of high-affinity sites (Bmax = 107 fmol/mg of protein and Kd = 0.99 nM) in cardiac membranes, with a specificity characteristic of dihydropyridine receptors. After incubation of membranes with the tracer (0.5 nM), addition of excess nifedipine (1 microM) caused a dissociation of [3H]oNCS-DHP from its binding site. The reversibility of [3H]oNCS-DHP binding was confirmed by the lack of affinity labeling of cardiac membranes as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis. oNCS-DHP inhibited the inward Ca++ current of isolated guinea pig cardiac myocytes as determined in voltage-clamp experiments. In isolated perfused guinea pig hearts, oNCS-DHP caused a concentration-dependent increase in coronary artery flow and a decrease in left ventricular pressure. The effects of the highest concentration (0.3 microM) were still near maximal after a 1-h washout. Suppression of K+ depolarization-induced contractures of isolated ileal longitudinal muscle strips by oNCS-DHP remained maximal even after 5 h of washout. In all of the three biological test systems investigated, the Ca++ channel activator Bay K 8644 caused a complete and rapid reversal of the inhibitory effects of oNCS-DHP. Thus, it can be concluded that oNCS-DHP does not bind irreversibly to Ca++ channel dihydropyridine receptors in guinea pig heart and ileum. However, the o-isothiocyanatophenyl substituent on the dihydropyridine molecule confers upon the compound a very long duration of Ca++ channel blocking activity.

Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

Cibenzoline, a class 1 (local anaesthetic-type) antiarrhythmic drug, was investigated for possible effects upon the myocardial Ca2+ inward current. In voltage-clamp experiments with isolated cardiac myocytes of guinea-pig, cibenzoline caused a concentration-dependent inhibition of the Ca2+ current, with an IC50 of 14 microM. Inhibition of the Ca2+ current by cibenzoline (2 microM) was dependent upon stimulation frequency, with a greater block occurring at 2 Hz (approximately 50%) than at 0.2 Hz (approximately 15%). The magnitude of Ca2+ current block was also potential-dependent. A markedly greater inhibition by cibenzoline (20 microM) was recorded when myocytes were depolarized (to +20 mV) from a holding potential of -35 mV than of -80 mV. At the less negative potential, cibenzoline also caused a reduction in the level of the holding current, which suggests a decrease in the inwardly rectifying K+ current. Cibenzoline also caused a concentration-dependent inhibition of KCl-induced contractures of isolated aortic strips of the rat (IC50 = 55 microM) and a reduction in contractile force of isolated, electrically-stimulated papillary muscles of the guinea-pig (IC50 = 35 microM). Thus, cibenzoline possesses Ca2+ channel blocking (class 4) properties in addition to its local anaesthetic actions.

The peripheral, high affinity benzodiazepine binding site is not coupled to the cardiac Ca2+ channel.

Ro 5-4864, the prototype ligand of the peripheral benzodiazepine binding site caused a decrease of the action potential duration in isolated guinea-pig cardiac myocytes. Voltage-clamp experiments showed that, at concentrations below 3 X 10(-6) M, Ro 5-4864 caused a parallel outward shift of the membrane current elicited by depolarization to + 10 mV from a holding potential of -50 mV. The peak inward Ca2+ current (ICa) and the inwardly rectifying K+ current were not affected. ICa was reduced by Ro 5-4864 at concentrations above 3 X 10(-6) M. At these concentrations, Ro 5-4864 also caused a negative inotropic effect in isolated guinea-pig papillary muscles, reduced K+ depolarization-induced contractures of the isolated rat aorta and inhibited [3H]nitrendipine binding to guinea-pig cardiac membranes. These data provide no evidence that the peripheral high affinity benzodiazepine binding site is coupled to the cardiac Ca2+ channel. The possibility cannot be excluded that a postulated micromolar affinity benzodiazepine receptor is associated with the Ca2+ channel.

Cardiac membrane currents and energetic state.

Adrenaline, cAMP and cAMP-dependent protein kinase modulate the slow inward Ca current by the same basic mechanism, presumably a phosphorylation of membrane proteins. Protein kinase also seems to play a role in the regulation of K outward currents, but not for the transient inward current.

Beta-adrenergic increase in the calcium conductance of cardiac myocytes studied with the patch clamp.

In bovine, cat and guinea pig myocytes the effect of bath application of adrenaline or isoprenaline and of injection of cAMP on the Ca channel was studied with the patch clamp (Hamill et al. 1981), and the following results were obtained. On beta-adrenergic stimulation more activity of the single channel on repeated depolarizations and less records without activity were observed. Correspondingly, the average currents were increased. When the patch contained only one channel as judged from the lack of superpositions during all depolarizations, beta-adrenergic stimulation never produced superpositions indicating that the total number of channels did not increase. Also, it was never possible to activate a channel in the mute patch. The single channel conductance was not changed by catecholamines or cAMP. Increase in probability during depolarization of the channel to be in the open state was proven by non-stationary fluctuation analysis. The kinetic analysis showed a prolongation of the open times and shortening of the shut times by catecholamines, indicating that the rate constants in a three state model C1 in equilibrium C2 in equilibrium O are changed in such a way that the equilibrium shifted towards the open state. In some patches clusters of channels were observed, and activity was greatly increased by adrenaline, isoprenaline and cAMP-injection. The decay of the mean current was either mono-exponential or, in most cases, double-exponential. When the decay was mono-exponential, fluctuation analysis showed an increase in open probability on beta-stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Injection of catalytic subunit of cAMP-dependent protein kinase into isolated cardiac myocytes.

Cyclic adenosine 3',5'-monophosphate (cAMP) or the free catalytic subunit (C) of the cAMP-dependent protein kinase were pressure injected into single guinea pig ventricular cells. The following results were obtained: Injection of cAMP prolonged the action potential and shifted the action potential plateau to a more positive level. Under voltage clamp, cAMP injection increased the amplitude of the slow inward calcium current (Isi). Injection of C permanently prolonged the action potential and enhanced the amplitude of Isi by a factor of 2-4, depending on the amount of injected C. In the current-voltage relations the potential of maximum Isi and the apparent current reversal did not change. After maximum prolongation of the action potential due to repeated injections of C, even high concentrations of adrenaline did not further change the configuration of the action potential. In many experiments transient depolarizations appeared after the injection. Correspondingly, under voltage clamp transient inward currents occurred. C injection increased both the time-dependent and time-independent potassium outward current. In response to injection of the catalytic subunit, the isotonic contraction was larger in amplitude and relaxation was faster. It is concluded that the cAMP-dependent protein kinase increases the slow inward calcium current in the heart, presumably by phosphorylation of some membrane proteins.